만성 B형 간질환 환자에서 라미부딘 1년 치료효과 = The Effect of One Year Lamivudine Therapy for Chronic Liver Disease due to Hepatitis B virus

다국어 초록 (Multilingual Abstract)

■ Objectives The aim of this study was to evaluate the biochemical and virological responses to one year lamivudine therapy in HBV-associated chronic liver diseases including interferon(IKF) -naive. INF-failed chronic hepatitis and liver cirrhosis.
■ Methods This study was conducted as an one-year trial of lamivudine in 60 patients with HBV-associated liver disease(INF-naive chronic hepatitis 20. INF-failed chronic hepatitis 18. liver cirrhosis 22). We classifed the patients as INF-naive chronic hepatitis(Group A), as INF-failed chronic hepatitis(Group B) and as liver cirrhosis(Group C).
■ Results The mean normalization rate of serum ALT was 71.7%: 65.0% in Group A. 61.1% in Group B and 86.4% in Group C. The negative conversion rate of HBV-DNA was 73.3%: 60.0% in Group A, 83.3% in Group B and 77.3% in Group C. The seroconversion rate of HBeAg was 30.0%: 22.2% in Group A, 35.3% in Group B and 26.3% in Group C. The breakthrough was occurred in 26.7% of patients: 40% in Group A, 16.7% in Group B and 22.7% in Group C. However, they did not deteriorate clinically in spite of ALT elevation and HBV-DNA reappearance. In case of anti-HBe positive chronic liver disease, ALT was normalized and HBV-DNA became undetactable in all 6 patients after 1 year lamivudine treatment.
■ Conclusions One year lamivudine treatment resulted in biochemical and virological improvements in patients with HBV- associated liver disease irrespective of the severity of liver disease and the status of HBeAg/Anti-HBe. Further studies are required to determine the effects of long-term suppressive therapy and optimal duration of therapy in patients with chronic HBV infection.